Clinical Trial Update: A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications [Phase 3]

View source ↗

Summary

Phase 3 study evaluating ABT-SLV187 as monotherapy in advanced Parkinson's disease with persistent motor complications; results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• ABT-SLV187

Snippet

Sponsor: AbbVie | Conditions: Advanced Parkinson's Disease | Phase 3 | Status: COMPLETED | Results posted: 2016-04-20